C4 Therapeutics Past Performance
How has C4 Therapeutics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-31.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CCCC is currently unprofitable.
Growing Profit Margin: CCCC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CCCC is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.
Accelerating Growth: Unable to compare CCCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CCCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: CCCC has a negative Return on Equity (-33.52%), as it is currently unprofitable.